Screening and mass spectrometry analysis of differentially expressed proteins of plasm between laryngocarcinoma and healthy individuals.
- Author:
Junzheng LI
1
;
Wendong TIAN
;
Xiong LIU
;
Shuiwang HU
;
Bao ZHANG
;
Xiangping LI
Author Information
1. Department of Otorhinolaryngology-Head and Neck Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
- Publication Type:Journal Article
- MeSH:
Biomarkers, Tumor;
blood;
Case-Control Studies;
Humans;
Laryngeal Neoplasms;
blood;
Male;
Mass Spectrometry;
Middle Aged;
Proteome;
metabolism;
Proteomics;
methods
- From:
Journal of Clinical Otorhinolaryngology Head and Neck Surgery
2013;27(14):771-774
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To compare and analyze the expression difference of proteins between laryngocarcinoma and healthy individuals to search for protein biomarkers that may be detected in plasm of laryngocarcinoma patients.
METHOD:Pooled plasm from 6 laryngocarcinoma patients and 6 healthy individuals as controls were collected. Two-dimensional gel electrophoresis (2-DE) was used to isolate the total proteins, and the differential protein spots were identified by MALDI-TOF/TOF mass spectrometer, and then the biological information of the proteins was analyzed.
RESULT:Twenty differential expressed protein spots with more than 1.5-fold between the laryngocarcinoma and healthy individuals were selected, and there were 8 proteins upregulated and 12 proteins downregulated among these proteins. After identifying by MALDI-TOF/TOF, compared with healthy controls, the spots that were L1, C-reactive protein, haptoglobin, ceruloplasmin; the spots that were downregulated were: Serotransferrin, alpha-2-HS-glycoprotein, fibrinogen gamma chain, haptoglobin related protein, Ig lambda-1 chain C regions, Ig kappa chain C region, apolipoprotein A-I, transthyretin, apolipoprotein C-III.
CONCLUSION:Compared with laryngocarcinoma and healthy individuals, the plasm proteins profile showed differently. The proteins of differential expressed are expected to be the specific plasm biomarkers for laryngocarcinoma patients.
